Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17094094 | 0.78 | ALDH1A1 (0.43) | KDM4ETDP1ALDH1A1TRPM8KEAP1 | |
| SCHEMBL4199277 | 0.71 | RAB9A (0.38) | KDM4EALDH1A1NPC1RAB9ACA12 | |
| SCHEMBL19210477 | 0.68 | TDP1 (0.44) | KDM4ETDP1ALDH1A1NPC1RAB9A | |
| SCHEMBL13365399 | 0.68 | NPC1 (0.33) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL3747791 | 0.67 | NPC1 (0.40) | ALDH1A1NPC1RAB9ACA12CA9 | |
| SCHEMBL19739531 | 0.66 | ALDH1A1 (0.44) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL28110750 | 0.65 | — | — | |
| SCHEMBL6204342 | 0.64 | KDM4E (0.52) | KDM4ETDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL19948822 | 0.64 | NPC1 (0.41) | KDM4ETDP1ALDH1A1NPC1RAB9A | |
| SCHEMBL5431495 | 0.63 | CA12 (0.50) | KDM4ETDP1ALDH1A1TRPM8NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511328-B1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2020-09-03 | — | — | US | disclosed |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20190231752-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3511328-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Novartis AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20160051523-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9174978-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231752-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | KDM4E 1808/4885TDP1 4313/4885ALDH1A1 431/4885 |
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | KDM4E 1808/4885TDP1 4313/4885ALDH1A1 431/4885 |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | MGAM, MGAM2, BPGM | KDM4E 1808/4885TDP1 4313/4885ALDH1A1 431/4885 |
| US-20160051523-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | KDM4E 1808/4885TDP1 4313/4885ALDH1A1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.